CoChat

The critical need for defining preclinical biomarkers in Alzheimer's disease

Open access
Fiandaca, Massimo S., Mapstone, Mark E., Cheema, Amrita K., Federoff, Howard J. · 2014 · Alzheimer's & Dementia
Cited by 131

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

The increasing number of afflicted individuals with late‐onset Alzheimer's disease (AD) poses significant emotional and financial burden on the world's population. Therapeutics designed to treat symptoms or alter the disease course have failed to make an impact, despite substantial investments by governments, pharmaceutical industry, and private donors. These failures in treatment efficacy have led many to believe that symptomatic disease, including both mild cognitive impairment (MCI) and AD, may be refractory to therapeutic intervention. The recent focus on biomarkers for defining the preclinical state of MCI/AD is in the hope of defining a therapeutic window in which the neural substrate remains responsive to treatment. The ability of biomarkers to adequately define the at‐risk state may ultimately allow novel or repurposed therapeutic agents to finally achieve the disease‐modifying status for AD. In this review, we examine current preclinical AD biomarkers and suggest how to generalize their use going forward.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2014.04.015

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 131

Metadata

Authors
Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., & Federoff, H. J.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-06
Volume
10
Issue
3S
Pages
S196-212
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W1965227180
Cited by
131
References
42
FWCI
10.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The critical need for defining preclinical biomarkers in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2014.04.015
The paper
Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., & Federoff, H. J. (2014). The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2014.04.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.